Address
FluoretiQ Limited
Science Creates- St Phillips
Albert Road, Bristol
BS2 0XJ, United Kingdom
United Kingdom
Contact
Neciah Dorh01174034077
n.dorh@fluoretiq.com
Website
NANOPLEX® and SCFI™
Our technology platforms (NANOPLEX® and SCFI™) rapidly identify the causative agent and suggest the most effective treatment in 30 minutes.
Our rapid ID (NANOPLEX®) and AST (SCFI™) platforms enable clinicians to prescribe responsibly and provide the highest quality of care to patients.
- Antimicrobial stewardship
- Microbial diagnostics
- Infection prevention
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Validation
- Research
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Outsource
- Sell
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- STI
- RTI
- SSTI
- BSI
- GII
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
For NANOPLEX we are looking to engage with partners who can help us setup clinical evaluations and expediate access into EU markets.
For SCFI we’re looking for partners to explore collaboration opportunities with our technology.
FluoretiQ specialises in the development of fast and accurate diagnostic platforms to combat antimicrobial resistance.
NANOPLEX® and SCFI™ form a complimentary AMR test suite that are fast, accurate and can be used at the point of care. Our first NANOPLEX product is heading to market later this year to identify Urinary Tract Infections.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!